The 2002 sequencing of the Human Genome revolutionized our understanding of human disease, giving us heretofore unknown information about the genetic drivers of disease and, by extension, direction on how to address it. This post will provide a snapshot of where we stand in drugging the druggable universe.
Our portfolio manager Jeff James talks with Oliver Renick on TD Ameritrade Network. View here!
EM equities are off to a strong start in 2019, but will the recent breakout of the US dollar be déjà vu all over again? We examine recent macro trends and portfolio positioning shifts through April.